Back to Search
Start Over
With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave.
- Source :
- FierceBiotech; 9/9/2024, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- Candid's launch combines fundraising and the acquisition of two biotechs, Vignette Bio and TRC 2004, along with their lead assets. [ABSTRACT FROM AUTHOR]
- Subjects :
- BISPECIFIC antibodies
AUTOIMMUNE diseases
RITUXIMAB
T cells
ADALIMUMAB
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- FierceBiotech
- Publication Type :
- Periodical
- Accession number :
- 179549501